From Drughunters winner to neuropsychologist

Every year, the Drughunters competition inspires high school students all over Denmark and ignites an interest that can pave the way for the neuroscience talents of tomorrow, such as Charlotte Amalie Børglum Sørensen.

Watch the video and learn more about Drughunters

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

LATEST NEWS

25 November, 2021 Feature
From Drughunters winner to neuropsychologist
15 November, 2021 Press Release
Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention
12 November, 2021 Corporate Release
Vyepti[®] recommended for approval in the EU by CHMP for the preventive treatment of migraine in adults

See All News

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Investors

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease.

Patients

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

jason F. houston on working at Lundbeck

Advocacy Makes the Difference

See All Stories

Lundbeck at a glance

100

countries where our products are sold

5,600

employees supporting our purpose

1915

year Lundbeck was founded

No Health Without Mental Health

A Strange Dream

A Small Caterpillar Taking Cover Under a Leaf

So Perfect, So Vulnerable